Gene · 28923
IGKV2-24: immunoglobulin kappa variable 2-24
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. IGKV2-24: immunoglobulin kappa variable 2-24. Genes, record 28923. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/28923
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| A0A0C4DH68 | Immunoglobulin kappa variable 2-24 | 120 | 0 | Ensembl, HGNC |
Source UniProt
Patents6
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 14310 | A0A0C4DH68 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 14310 | A0A0C4DH68 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 39834 | A0A0C4DH68 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 39835 | A0A0C4DH68 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 142805 | A0A0C4DH68 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 142806 | A0A0C4DH68 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants779
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IGKV2-24 papers | Newest fiscal year |
|---|---|---|---|
| ZIAAI000986 | Influenza Viral Pathogenesis | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA138313 | Medical University of South Carolina - Cancer Center Support Grant | 3 | 2025 |
| P30DK123704 | MUSC Digestive Disease Research Core Center | 3 | 2025 |
| R01AI165692 | Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions | 3 | 2025 |
| R01CA160254 | Serum Glyco-Markers of Early Hepatocellular Carcinoma Using a Mass Spec Approach | 3 | 2025 |
| R01GM082946 | AAV capsids and their cellular interactions | 3 | 2025 |
| T32GM132055 | Cellular, Biochemical and Molecular Sciences Training Program | 3 | 2025 |
| ZIAAI000307 | Poxvirus Biology | 3 | 2025 |
| ZIAAI005022 | Antibody Neutralization Mechanisms | 3 | 2025 |
1 to 10 of 779Source NIH's project files
See all 779 nih grantsPapers1,286
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| α2,3-sialylation on human naïve T cells restrains bispecific engager-mediated anti-tumor immunity. | bioRxiv | 2026 | 42620328 | PubTator, text mining | PubMed |
| Programmable One-Tube Sialic Acid Derivatization Enables Dual-Mode N-Glycomics of Low-Input Samples. | Anal Chem | 2026 | 42578856 | PubTator, text mining | PubMed |
| Sialic Acid Linkage-Specific Alkylamidation-Based Method for N- and O-Glycoproteomic Profiling of Human Plasma. | Anal Chem | 2026 | 42421262 | PubTator, text mining | PubMed |
| Bioorthogonal labeling of sialic acid isomers for detection of glycoconjugates by mass spectrometry imaging and microscopy. | Methods Enzymol | 2026 | 42349971 | PubTator, text mining | PubMed |
| Galacto-Oligosaccharides Reshape Mucin O-Glycan Profiles to Enhance Small Intestinal Barrier Development in Early Life. | J Agric Food Chem | 2026 | 42284521 | PubTator, text mining | PubMed |
| α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades. | Int J Gynaecol Obstet | 2026 | 42080626 | PubTator, text mining | PubMed |
| De novo biosynthesis of 3'-sialyllactosamine in Escherichia coli via integrated metabolic and protein engineering. | Bioresour Technol | 2026 | 42013939 | PubTator, text mining | PubMed |
| Increased levels of α2-3- and α2-6-linked sialic acids during airway inflammation govern influenza A binding to peripheral airway mucins in a subtype-dependent manner. | Front Immunol | 2026 | 41909675 | PubTator, text mining | PubMed |
| Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. | Cell Rep Med | 2026 | 41850238 | PubTator, text mining | PubMed |
| Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression. | Front Immunol | 2026 | 41789075 | PubTator, text mining | PubMed |
1 to 10 of 1,286
See all 1,286 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/28923
GET https://conductscience.org/api/genes/v1/28923/grants?page=2